When a highly potent new opioid formulation was approved by his agency on Nov. 2, FDA Commissioner Scott Gottlieb, M.D., downplayed safety concerns about AcelRx’s Dsuvia. He stressed the importance of the painkiller for military use and the “very tight restrictions being placed on the distribution and use of this product.” In general, PBM and […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.